南昌社区中老年人群糖尿病流行病学调查中HbA1C对诊断2型糖尿病的价值

选择南昌1 415例中老年人作为研究对象,分为正常糖耐量组、糖调节受损组及糖尿病组.结果 显示,HbA1C与空腹血糖(FPG)及餐后2 h血糖呈显著相关,HbA1C 6.3%诊断糖尿病的敏感度为85.19%,特异度为99.45%,HbA1C 6.5%诊断糖尿病的敏感度为75.56%,特异度为99.61%.在本研究的人群中,HbA1C 6.3%诊断糖尿病较HbA1C 6.5%及FPG 7.0 mmol/L具有更高的敏感性.

Abstract：

A total of1415 elderly individuals in Nanchang were included in the study and were divided into normal glucose tolerance group, impaired glucose regulation group, and diabetes mellitus group.The results showed that HbA1C was significantly correlated with fasting plasma glucose (FPG) and 2 h postprandial plasma glucose.When HbA1C 6.3% was applied as the cut point of diabetes, the sensitivity was 85.19% and the specifity was 99.45%.When HbA1C 6.5% was applied, the sensitivity was 75.56% and specifity was 99.61%.It seems that HbA1C 6.3% had higher specifity and sensitivity for diagnosing diabetes than HbA1C 6.5% and FPG 7.0mmol/L in studied population.     

中国门诊2型糖尿病患者口服药降糖达标状况调查及格列齐特缓释片优化治疗效果分析

Objective To evaluate the current state of glycemie control in Chinese patients with type 2 diabetes mellitus who have received oral antidiabetic agents in the out-patient clinic,and the efficacy and safety of optimized regiments of gliclazide modified-release tablets (Diamicron MR, SERVIER, Tianjin) in patients with failed glycemic control (HbA1c 6.5%). Methods The patients with type 2 diabetes were enrolled from 54 hospitals in more than 20 cities and received long-term (more than 3 months) oral antidiabetic agents. HbA1c was measured and the success rate of HbA1c reduction was evaluated. The patients who failed to achieve glycemic control (HbA1c 6. 5%) and received daily multiple-dosing insulin secretagogues were provided with the optimized treatment regimen, consisting of replacing daily multiple-dosing insulin secretagogues with single-dosing gliclazide sustained-release tablets. Clinical efficacy and safety were evaluated after three months treatment. Results The survey of glycemic control revealed that the mean HbA1c of 5 586 patients with diabetes mellitus was (7.97±2.89)% ,and the success rate (HbA1c≤6.5%) was 14. 1%. Further more, HbA1c decreased from (8.23±4.00)% before optimization to (6.86±2.24)% after optimization with the average decrement of 1.37% (P<0. 001) and the success rate was raised to 34. 1%. The gliclazide modified-release tablets were well tolerated by most patients, only 2.6% of whom were reported to experience unconfirmed hypoglycemia. Conclusion The success rate of glycemic control was low in Chinese out-patients with type 2 diabetes mellitus receiving oral antidiabetic agents in the clinic. The optimized regimen of gliclazide modified-release tablets taken once daily can down-regulate glycemic levels and increase the success rate of HbA1c reduction,and thus plays efficiently and safely a key role in the optimized management of type 2 diabetes mellitus.     

中国门诊2型糖尿病患者口服药降糖达标状况调查及格列齐特缓释片优化治疗效果分析

Objective To evaluate the current state of glycemie control in Chinese patients with type 2 diabetes mellitus who have received oral antidiabetic agents in the out-patient clinic,and the efficacy and safety of optimized regiments of gliclazide modified-release tablets (Diamicron MR, SERVIER, Tianjin) in patients with failed glycemic control (HbA1c 6.5%). Methods The patients with type 2 diabetes were enrolled from 54 hospitals in more than 20 cities and received long-term (more than 3 months) oral antidiabetic agents. HbA1c was measured and the success rate of HbA1c reduction was evaluated. The patients who failed to achieve glycemic control (HbA1c 6. 5%) and received daily multiple-dosing insulin secretagogues were provided with the optimized treatment regimen, consisting of replacing daily multiple-dosing insulin secretagogues with single-dosing gliclazide sustained-release tablets. Clinical efficacy and safety were evaluated after three months treatment. Results The survey of glycemic control revealed that the mean HbA1c of 5 586 patients with diabetes mellitus was (7.97±2.89)% ,and the success rate (HbA1c≤6.5%) was 14. 1%. Further more, HbA1c decreased from (8.23±4.00)% before optimization to (6.86±2.24)% after optimization with the average decrement of 1.37% (P<0. 001) and the success rate was raised to 34. 1%. The gliclazide modified-release tablets were well tolerated by most patients, only 2.6% of whom were reported to experience unconfirmed hypoglycemia. Conclusion The success rate of glycemic control was low in Chinese out-patients with type 2 diabetes mellitus receiving oral antidiabetic agents in the clinic. The optimized regimen of gliclazide modified-release tablets taken once daily can down-regulate glycemic levels and increase the success rate of HbA1c reduction,and thus plays efficiently and safely a key role in the optimized management of type 2 diabetes mellitus.     

中国门诊2型糖尿病患者口服药降糖达标状况调查及格列齐特缓释片优化治疗效果分析

Objective To evaluate the current state of glycemie control in Chinese patients with type 2 diabetes mellitus who have received oral antidiabetic agents in the out-patient clinic,and the efficacy and safety of optimized regiments of gliclazide modified-release tablets (Diamicron MR, SERVIER, Tianjin) in patients with failed glycemic control (HbA1c 6.5%). Methods The patients with type 2 diabetes were enrolled from 54 hospitals in more than 20 cities and received long-term (more than 3 months) oral antidiabetic agents. HbA1c was measured and the success rate of HbA1c reduction was evaluated. The patients who failed to achieve glycemic control (HbA1c 6. 5%) and received daily multiple-dosing insulin secretagogues were provided with the optimized treatment regimen, consisting of replacing daily multiple-dosing insulin secretagogues with single-dosing gliclazide sustained-release tablets. Clinical efficacy and safety were evaluated after three months treatment. Results The survey of glycemic control revealed that the mean HbA1c of 5 586 patients with diabetes mellitus was (7.97±2.89)% ,and the success rate (HbA1c≤6.5%) was 14. 1%. Further more, HbA1c decreased from (8.23±4.00)% before optimization to (6.86±2.24)% after optimization with the average decrement of 1.37% (P<0. 001) and the success rate was raised to 34. 1%. The gliclazide modified-release tablets were well tolerated by most patients, only 2.6% of whom were reported to experience unconfirmed hypoglycemia. Conclusion The success rate of glycemic control was low in Chinese out-patients with type 2 diabetes mellitus receiving oral antidiabetic agents in the clinic. The optimized regimen of gliclazide modified-release tablets taken once daily can down-regulate glycemic levels and increase the success rate of HbA1c reduction,and thus plays efficiently and safely a key role in the optimized management of type 2 diabetes mellitus.     

中国门诊2型糖尿病患者口服药降糖达标状况调查及格列齐特缓释片优化治疗效果分析

Objective To evaluate the current state of glycemie control in Chinese patients with type 2 diabetes mellitus who have received oral antidiabetic agents in the out-patient clinic,and the efficacy and safety of optimized regiments of gliclazide modified-release tablets (Diamicron MR, SERVIER, Tianjin) in patients with failed glycemic control (HbA1c 6.5%). Methods The patients with type 2 diabetes were enrolled from 54 hospitals in more than 20 cities and received long-term (more than 3 months) oral antidiabetic agents. HbA1c was measured and the success rate of HbA1c reduction was evaluated. The patients who failed to achieve glycemic control (HbA1c 6. 5%) and received daily multiple-dosing insulin secretagogues were provided with the optimized treatment regimen, consisting of replacing daily multiple-dosing insulin secretagogues with single-dosing gliclazide sustained-release tablets. Clinical efficacy and safety were evaluated after three months treatment. Results The survey of glycemic control revealed that the mean HbA1c of 5 586 patients with diabetes mellitus was (7.97±2.89)% ,and the success rate (HbA1c≤6.5%) was 14. 1%. Further more, HbA1c decreased from (8.23±4.00)% before optimization to (6.86±2.24)% after optimization with the average decrement of 1.37% (P<0. 001) and the success rate was raised to 34. 1%. The gliclazide modified-release tablets were well tolerated by most patients, only 2.6% of whom were reported to experience unconfirmed hypoglycemia. Conclusion The success rate of glycemic control was low in Chinese out-patients with type 2 diabetes mellitus receiving oral antidiabetic agents in the clinic. The optimized regimen of gliclazide modified-release tablets taken once daily can down-regulate glycemic levels and increase the success rate of HbA1c reduction,and thus plays efficiently and safely a key role in the optimized management of type 2 diabetes mellitus.     

中国门诊2型糖尿病患者口服药降糖达标状况调查及格列齐特缓释片优化治疗效果分析

Objective To evaluate the current state of glycemie control in Chinese patients with type 2 diabetes mellitus who have received oral antidiabetic agents in the out-patient clinic,and the efficacy and safety of optimized regiments of gliclazide modified-release tablets (Diamicron MR, SERVIER, Tianjin) in patients with failed glycemic control (HbA1c 6.5%). Methods The patients with type 2 diabetes were enrolled from 54 hospitals in more than 20 cities and received long-term (more than 3 months) oral antidiabetic agents. HbA1c was measured and the success rate of HbA1c reduction was evaluated. The patients who failed to achieve glycemic control (HbA1c 6. 5%) and received daily multiple-dosing insulin secretagogues were provided with the optimized treatment regimen, consisting of replacing daily multiple-dosing insulin secretagogues with single-dosing gliclazide sustained-release tablets. Clinical efficacy and safety were evaluated after three months treatment. Results The survey of glycemic control revealed that the mean HbA1c of 5 586 patients with diabetes mellitus was (7.97±2.89)% ,and the success rate (HbA1c≤6.5%) was 14. 1%. Further more, HbA1c decreased from (8.23±4.00)% before optimization to (6.86±2.24)% after optimization with the average decrement of 1.37% (P<0. 001) and the success rate was raised to 34. 1%. The gliclazide modified-release tablets were well tolerated by most patients, only 2.6% of whom were reported to experience unconfirmed hypoglycemia. Conclusion The success rate of glycemic control was low in Chinese out-patients with type 2 diabetes mellitus receiving oral antidiabetic agents in the clinic. The optimized regimen of gliclazide modified-release tablets taken once daily can down-regulate glycemic levels and increase the success rate of HbA1c reduction,and thus plays efficiently and safely a key role in the optimized management of type 2 diabetes mellitus.     

中国门诊2型糖尿病患者口服药降糖达标状况调查及格列齐特缓释片优化治疗效果分析

Objective To evaluate the current state of glycemie control in Chinese patients with type 2 diabetes mellitus who have received oral antidiabetic agents in the out-patient clinic,and the efficacy and safety of optimized regiments of gliclazide modified-release tablets (Diamicron MR, SERVIER, Tianjin) in patients with failed glycemic control (HbA1c 6.5%). Methods The patients with type 2 diabetes were enrolled from 54 hospitals in more than 20 cities and received long-term (more than 3 months) oral antidiabetic agents. HbA1c was measured and the success rate of HbA1c reduction was evaluated. The patients who failed to achieve glycemic control (HbA1c 6. 5%) and received daily multiple-dosing insulin secretagogues were provided with the optimized treatment regimen, consisting of replacing daily multiple-dosing insulin secretagogues with single-dosing gliclazide sustained-release tablets. Clinical efficacy and safety were evaluated after three months treatment. Results The survey of glycemic control revealed that the mean HbA1c of 5 586 patients with diabetes mellitus was (7.97±2.89)% ,and the success rate (HbA1c≤6.5%) was 14. 1%. Further more, HbA1c decreased from (8.23±4.00)% before optimization to (6.86±2.24)% after optimization with the average decrement of 1.37% (P<0. 001) and the success rate was raised to 34. 1%. The gliclazide modified-release tablets were well tolerated by most patients, only 2.6% of whom were reported to experience unconfirmed hypoglycemia. Conclusion The success rate of glycemic control was low in Chinese out-patients with type 2 diabetes mellitus receiving oral antidiabetic agents in the clinic. The optimized regimen of gliclazide modified-release tablets taken once daily can down-regulate glycemic levels and increase the success rate of HbA1c reduction,and thus plays efficiently and safely a key role in the optimized management of type 2 diabetes mellitus.     

中国门诊2型糖尿病患者口服药降糖达标状况调查及格列齐特缓释片优化治疗效果分析

Objective To evaluate the current state of glycemie control in Chinese patients with type 2 diabetes mellitus who have received oral antidiabetic agents in the out-patient clinic,and the efficacy and safety of optimized regiments of gliclazide modified-release tablets (Diamicron MR, SERVIER, Tianjin) in patients with failed glycemic control (HbA1c 6.5%). Methods The patients with type 2 diabetes were enrolled from 54 hospitals in more than 20 cities and received long-term (more than 3 months) oral antidiabetic agents. HbA1c was measured and the success rate of HbA1c reduction was evaluated. The patients who failed to achieve glycemic control (HbA1c 6. 5%) and received daily multiple-dosing insulin secretagogues were provided with the optimized treatment regimen, consisting of replacing daily multiple-dosing insulin secretagogues with single-dosing gliclazide sustained-release tablets. Clinical efficacy and safety were evaluated after three months treatment. Results The survey of glycemic control revealed that the mean HbA1c of 5 586 patients with diabetes mellitus was (7.97±2.89)% ,and the success rate (HbA1c≤6.5%) was 14. 1%. Further more, HbA1c decreased from (8.23±4.00)% before optimization to (6.86±2.24)% after optimization with the average decrement of 1.37% (P<0. 001) and the success rate was raised to 34. 1%. The gliclazide modified-release tablets were well tolerated by most patients, only 2.6% of whom were reported to experience unconfirmed hypoglycemia. Conclusion The success rate of glycemic control was low in Chinese out-patients with type 2 diabetes mellitus receiving oral antidiabetic agents in the clinic. The optimized regimen of gliclazide modified-release tablets taken once daily can down-regulate glycemic levels and increase the success rate of HbA1c reduction,and thus plays efficiently and safely a key role in the optimized management of type 2 diabetes mellitus.     

中国门诊2型糖尿病患者口服药降糖达标状况调查及格列齐特缓释片优化治疗效果分析

Objective To evaluate the current state of glycemie control in Chinese patients with type 2 diabetes mellitus who have received oral antidiabetic agents in the out-patient clinic,and the efficacy and safety of optimized regiments of gliclazide modified-release tablets (Diamicron MR, SERVIER, Tianjin) in patients with failed glycemic control (HbA1c 6.5%). Methods The patients with type 2 diabetes were enrolled from 54 hospitals in more than 20 cities and received long-term (more than 3 months) oral antidiabetic agents. HbA1c was measured and the success rate of HbA1c reduction was evaluated. The patients who failed to achieve glycemic control (HbA1c 6. 5%) and received daily multiple-dosing insulin secretagogues were provided with the optimized treatment regimen, consisting of replacing daily multiple-dosing insulin secretagogues with single-dosing gliclazide sustained-release tablets. Clinical efficacy and safety were evaluated after three months treatment. Results The survey of glycemic control revealed that the mean HbA1c of 5 586 patients with diabetes mellitus was (7.97±2.89)% ,and the success rate (HbA1c≤6.5%) was 14. 1%. Further more, HbA1c decreased from (8.23±4.00)% before optimization to (6.86±2.24)% after optimization with the average decrement of 1.37% (P<0. 001) and the success rate was raised to 34. 1%. The gliclazide modified-release tablets were well tolerated by most patients, only 2.6% of whom were reported to experience unconfirmed hypoglycemia. Conclusion The success rate of glycemic control was low in Chinese out-patients with type 2 diabetes mellitus receiving oral antidiabetic agents in the clinic. The optimized regimen of gliclazide modified-release tablets taken once daily can down-regulate glycemic levels and increase the success rate of HbA1c reduction,and thus plays efficiently and safely a key role in the optimized management of type 2 diabetes mellitus.     

中国门诊2型糖尿病患者口服药降糖达标状况调查及格列齐特缓释片优化治疗效果分析

Objective To evaluate the current state of glycemie control in Chinese patients with type 2 diabetes mellitus who have received oral antidiabetic agents in the out-patient clinic,and the efficacy and safety of optimized regiments of gliclazide modified-release tablets (Diamicron MR, SERVIER, Tianjin) in patients with failed glycemic control (HbA1c 6.5%). Methods The patients with type 2 diabetes were enrolled from 54 hospitals in more than 20 cities and received long-term (more than 3 months) oral antidiabetic agents. HbA1c was measured and the success rate of HbA1c reduction was evaluated. The patients who failed to achieve glycemic control (HbA1c 6. 5%) and received daily multiple-dosing insulin secretagogues were provided with the optimized treatment regimen, consisting of replacing daily multiple-dosing insulin secretagogues with single-dosing gliclazide sustained-release tablets. Clinical efficacy and safety were evaluated after three months treatment. Results The survey of glycemic control revealed that the mean HbA1c of 5 586 patients with diabetes mellitus was (7.97±2.89)% ,and the success rate (HbA1c≤6.5%) was 14. 1%. Further more, HbA1c decreased from (8.23±4.00)% before optimization to (6.86±2.24)% after optimization with the average decrement of 1.37% (P<0. 001) and the success rate was raised to 34. 1%. The gliclazide modified-release tablets were well tolerated by most patients, only 2.6% of whom were reported to experience unconfirmed hypoglycemia. Conclusion The success rate of glycemic control was low in Chinese out-patients with type 2 diabetes mellitus receiving oral antidiabetic agents in the clinic. The optimized regimen of gliclazide modified-release tablets taken once daily can down-regulate glycemic levels and increase the success rate of HbA1c reduction,and thus plays efficiently and safely a key role in the optimized management of type 2 diabetes mellitus.     

江苏省2型糖尿病患者血糖控制及治疗用药情况调查

目的了解江苏省2型糖尿病（T2DM）患者的血糖控制情况,分析治疗方法与血糖控制的关系。方法采用横断面研究方法,以调查问卷形式收集患者年龄、病程、降糖药物的使用情况等,留取血标本检测HbA1c。根据HbA1c水平将患者分为达标组（HbA1c〈6．5％）和未达标组（HbA1c≥6．5％）;根据降糖治疗情况分为胰岛素（Ins）组、胰岛素联用口服降糖药（Ins＋OA）组、口服降糖药（OA）组、生活方式干预（LS）组。结果入选T2DM患者2966例,年龄（56．4±11．2）岁,糖尿病平均病程（6．3±5．7）年,HbA1c值（7．2±1．6）％,HbA1c≥6．5％的患者占59．8％。（1）平均病程Ins组[（7．6±6．5）年]与Ins＋OA组[（8．2±6．2）年]均高于OA组C（5．3±5．0）年]（P〈0．01）。HbA1c均值及未达标比例Ins组[（7．4±1．6）％,未达标比例65．9％]与Ins＋OA组[（7．5±1．5）％,未达标比例77．9％]均高于OA组[（7．0±1．6）％,未达标比例52．4％]（P〈0．01）。（2）HbA1c达标组与未达标组病程分别为（4．8±4．9）年和（7．3±6．1）年（P〈0．01）,两组中胰岛素联合口服降糖药治疗者分别占11．5％和27．2％（P〈0．01）,单用胰岛素治疗者分别占17．0％和22．1％（P〈0．01）。结论江苏省T2DM患者血糖控制现状比3年前全国调查情况有所改善,但仍有相当比例的患者HbA1c水平没有达到IDF及《中国2型糖尿病防治指南》推荐标准。接受胰岛素治疗的患者HbA1c均值及不达标比例明显高于其他治疗组,表明由于病程延长及口服降糖药用药失效导致病情恶化后,再选择胰岛素治疗,血糖控制情况并不理想。     

中国门诊2型糖尿病患者口服药降糖达标状况调查及格列齐特缓释片优化治疗效果分析

目的 评估中国门诊2型糖尿病患者口服药降糖达标的现状,评价格列齐特缓释片[达美康缓释片,施维雅(天津)制药有限公司]一天一次的优化降糖方案的疗效及安全性.方法 在全国20多个城市的54家医院通过义诊调查门诊口服药治疗(3个月以上)的2型糖尿病患者,评估HbA1c≤6.5%的达标率;对未达标患者入组优化治疗,即采用一天一次的格列齐特缓释片治疗替换每日多次服用的促分泌药物(磺脲类或格列奈类药物),治疗3个月后评价其临床疗效及安全性.结果 血糖控制现状调查显示,5 586名2型糖尿病患者的HbA1c为(7.97±2.89)%,达标率为14.1%.1 721例未达标的患者进行优化治疗后,HbA1c从优化前(8.23±4.00)%降为(6.86±2.24)%,平均值下降1.37%(P<0.001),达标率提高为34.1%;空腹血糖从(8.87±4.65)mmol/L下降为(7.13±5.82)mmol/L;餐后2 h血糖从(12.50±4.00)mmoL/L下降为(8.96±3.61)mmol/L;仅有2.6%的患者报告可疑低血糖发生.结论 目前中国门诊口服药治疗的2型糖尿病患者的血糖控制达标率较低;采用每日一次的格列齐特缓释片优化治疗方案,能安全有效地降低血糖,提高HbA1c达标率,对于优化2型糖尿病的管理有重要意义.     

双时相门冬胰岛素30每日1次对2型糖尿病患者的疗效和安全性

目的 评价2型糖尿病患者每日1次应用双时相门冬胰岛素30治疗的有效性和安全性.方法 本研究为多中心、开放性、自身对照的临床观察性研究.2008年9月至2009年6月选取未接受降糖治疗或既往口服降糖药治疗血糖控制效果欠佳的2型糖尿病患者621例,平均年龄（56±11）岁,平均糖尿病病程（4.4±4.2）年（0～30年）,平均体重指数（25.5±2.9）kg/m2,平均糖化血红蛋白（HbA1c）8.5%±1.2%.使用每日1次双时相门冬胰岛素30,起始剂量和最终剂量分别为（0.16±0.05）U/kg、（0.20±0.07）U/kg.联合口服药治疗12周后评价其有效性和安全性,并探索不同基线因素对于疗效的影响.结果 治疗12周后,HbA1c下降了1.8%±1.1%.HbA1c＜6.5%的患者占30.8%,HbA1c＜7%的患者占65.5%.空腹血糖和餐后血糖均显著下降,8时点血糖平均值下降了（3.8±2.3）mmol/L.分别按基线糖尿病病程、HbA1c、注射时间和体重指数分层的分析结果显示,HbA1c达标率随着糖尿病病程的延长和HbA1c的升高而降低.在双时相门冬胰岛索30治疗中,非重度低血糖事件每年每例患者的发生率为1.83次.仅有1例（0.2%）患者发生1次重度（夜间）低血糖事件.患者治疗后体重较治疗前显著降低（P=0.0053）.结论 在未使用降糖治疗或已用口服降糖药但血糖控制不佳的2型糖尿病患者中,双时相门冬胰岛素30每日1次治疗作为胰岛素起始方案,可安全有效地降低血糖水平,尤其适用于HbA1c水平轻至中度升高,病程相对较短的患者.     

北京市社区40岁以上2型糖尿病患者血糖达标率的调查研究

目的 了解北京市部分社区40岁以上2型糖尿病患者血糖达标率的现状.方法 2011年12月至2012年8月在北京的三个社区（古城社区、金鼎社区、老山社区）的卫生服务中心通过普查的形式对40岁以上人群19 470名进行2型糖尿病相关的调查.符合标准的2 534名居民接受问卷调查、体格检查、实验室检查[肝肾功能、血糖、血脂、糖化血红蛋白（HbA1c）]等项目.选择人群中问卷调查结果为2型糖尿病（T2DM）的居民,以HbA1c＜7％为达标标准对其进行血糖达标率的分析,组间比较采用t检验及方差分析,logistic回归模型分析与血糖达标率可能相关的因素.结果 共入选2 523例2型糖尿病患者,平均HbA1c为（7.4±1.8）％,其中血糖达标率为45.7％.调查中发现仅用口服降糖药组、仅用胰岛素组、胰岛素＋口服降糖药组的平均HbA1c分别为（7.4＋1.6）％、（7.9±2.2）％、（7.9±2.0）％,达标率分别是47.2％（568/1 203）、32.5％（87/268）、26.4％（73/276）;单药降糖、双药降糖以及3种以上降糖药物控制的患者的HbA1c分别为（7.3±1.5）％、（7.5±1.9）％、（7.5±1.2）％,血糖达标率分别为45.0％（472/1049）、39.6％ （149/376）、37.0％（20/54）.病程＜1年、1～5年、5～ 10年、≥10年的患者HbA1c分别为（7.0±1.5）％、（7.1±1.6）％、（7.4±1.8）％、（7.8±1.9）％,达标率分别为56.4％（195/346）、55.5％（422/760）、44.7％（266/595）、32.8％（270/822）.logistic回归分析结果显示女性、体质指数、腰臀比、收缩压、并发症/伴发症、糖尿病病程、治疗方案与HbA1c达标率呈现相关性（OR=1.320、0.762、0.027、0.992、1.264、0.431、0.432,均P＜0.05）.结论 社区40岁以上人群中T2DM患者血糖达标率不足一半.随着糖尿病病程的延长,糖尿病的达标率不断下降.     

江苏省各级医院2型糖尿病患者口服降糖药物使用情况分析

目的 了解江苏省单用口服降糖药物（OAD）的T2DM患者的用药情况和血糖控制状况。 方法 选取江苏省13个城市各级医院门诊T2DM患者2966例进行横断面研究,以问卷形式收集患者个人信息、病程资料、治疗及合并症情况,检测HbA1c。 结果 单用OAD患者1524例,平均HbA1c（7.0±1.5）%。高脂血症患病率56.2%,高血压患病率41.4%。63.6%患者HbA1c达标（HbA1c〈7.0%）。20-40岁组HbA1c达标率高于41-60、61-80岁组（P〈0.05）。病程≤5年组HbA1c达标率高于5-10、〉10年组（P〈0.05）。双胍类药物在OAD中所占比例最高,且在各级医院所占比例亦最高。 结论 2009年单用OAD患者的HbA1c达标率高于2010年全国达标率,年轻及短病程患者改善尤为明显。双胍类药物在OAD中使用仍占首位。     

Which factors predict glycemic control in children diagnosed with type 1 diabetes before 6.5 years of age?

Predictors of long-term glycemic control and growth patterns in children diagnosed with type 1 diabetes (T1D) before 6.5?years of age were evaluated. One hundred seventy-three children (84 boys) with a mean diabetes duration of 4.9?±?2.8?years participated in this observational study. Medical charts were reviewed for background, disease- and treatment-related parameters, and growth parameters. Study endpoints were HbA1c value, rates of severe hypoglycemia and diabetic ketoacidosis events, and growth patterns. Mean HbA1c for the total duration of diabetes (HbA1c-TDD) was 7.9?±?0.8%. Comparison of the study variables between patients with HbA1c-TDD <7.5% (n?=?53) or ≥7.5% yielded a significantly shorter duration of diabetes (P?=?0.01) and lower rate of diabetic ketoacidosis (P?=?0.02) in those with HbA1C-TDD <7.5%, without differences between these groups in age at diabetes onset, insulin regimens, daily glucose measurements, and rate of severe hypoglycemia. Factors significantly predicting achievement of the mean target HbA1c-TDD <7.5% were lower HbA1c at 0.5?years and 1?year after diabetes diagnosis (P?=?0.002 and P?相似文献   

The rational treatment of diabetes mellitus in older adults: The adequacy of treatment decisions based on individualized glycemic targets in primary and tertiary care

ObjectivesTo access the adequacy of treatment decisions in accordance with current recommendations for individualizing glycemic targets in primary and tertiary care.MethodsThis multicenter cross-sectional study was conducted with a cohort of older type 2 diabetes patients from southern Brazil. Inclusion criteria were age over 65 years, having a previous diagnosis of type 2 diabetes (according to ADA criteria) and having at least two consultations registered in the medical records within one year. The primary outcome was the adequacy of treatment decisions according to pre-established HbA1c targets, which was compared with the complexity of care. The ideal HbA1c targets were: (1) 7–7.5% for an estimated life expectancy >10 years; (2) 7.5–8% for a life expectancy of 5–10 years; (3) 8–8.5% for a life expectancy <5 years. For analysis, the chi-square test was used for categorical variables and the t-test was used for continuous variables.ResultsOverall, 49.1% and 50.3% of the patients in the primary and tertiary care groups, respectively, received inadequate management. In patients whose HbA1c level was over target, the treatment was intensified in 46.3% and 51.2% of the primary and tertiary care groups, respectively (p = 0.57). In patients whose HbA1c level was under target, treatment was de-intensified in 5.9% and 26.2% in the primary and tertiary care groups, respectively (p <0.01).ConclusionTreatment changes based on individualized glycemic targets do occur in a minority of patients, which reflects the need for new strategies to facilitate individualized treatment targets and optimize the treatment adequacy in older adults.     

格列吡嗪控释片治疗2型糖尿病有效性和安全性的多中心临床研究

目的 评价格列吡嗪控释片(瑞易宁)治疗2型糖尿病的有效性、安全性.方法 为多中心、开放性临床观察性研究.675例患者完成了本研究.对单纯生活方式干预(n=134)或已用非胰岛素促泌剂(n=305)治疗,但血糖控制不佳的患者,加用瑞易宁;对已用其他磺脲类或格列奈类促泌剂(n=236)治疗,但血糖控制不佳、安全性不好或生活...     

口服降糖药联合甘精胰岛素及餐前一次门冬胰岛素的治疗达标研究——1+1研究

目的 观察2型糖尿病患者经口服降糖药联合甘精胰岛素治疗仍未达标时,于餐前增加1次门冬胰岛素的有效性、安全性和可行性.方法 采用多中心、开放、自身对照的方法.59例经口服降糖药及甘精胰岛素治疗而糖化血红蛋白(Hb)A1c＞6.5%但＜9%的患者,于主餐前加用门冬胰岛素治疗16周.结果 16周后,患者HbA1c由治疗前的(...     

那格列奈单药或序贯二甲双胍治疗对初诊2型糖尿病患者血糖稳定性的影响

观察那格列奈单药或序贯二甲双胍治疗对初诊2型糖尿病患者血糖稳定性的影响.对34例初诊2型糖尿病患者予口服那格列奈治疗,血糖不达标者再序贯加用二甲双胍,患者分为那格列奈单药组(单药组,14例)和那格列奈序贯二甲双胍组(双药组,20例).以HbA1C及动态血糖谱中日内平均血糖波动幅度(MAGE)联合反映患者血糖稳定性.患者治疗前及治疗3个月后检测血糖稳定性指标.经过治疗后两组MAGE、HbA1C均较治疗前明显改善(P＜0.05).使用那格列奈单药或序贯二甲双胍治疗能有效改善初诊2型糖尿病患者的血糖稳定性.

Abstract：

The effect of nateglinide or sequential treatment with metformin on glycemic stability in newly diagnosed type 2 diabetes was investigated. Thirty-four cases of newly diagnosed type 2 diabetes received nateglinide therapy, or sequential treatment with metformin according to fasting and postprandial blood glucose, and were classified into isolated nateglinide therapy group(n=14) and sequentially treated with metformin group(n=20). Glycemic stability, reflected by mean amplitude of glycemic excursions(MAGE) and HbA1C, was determined in all patients before and after therapy for three months. HbA1C and MAGE in two groups were all improved after treatment(P＜0.05). The therapy of nateglinide alone or combined with metformin can significantly improve glycemic stability in newly diagnosed type 2 diabetes.